Chen Jiaoquan, Zeng Xin, Chen Quan, Liang Bihua, Peng Liqian, Li Huaping, Tang Yi, Ou Shanshan, Zhu Huilan
Institute of Dermatology, Guangzhou Medical University, Guangzhou, 510095, Guangdong, China.
Department of Dermatology, Guangzhou Institute of Dermatology, Guangzhou, 510095, Guangdong, China.
Dermatol Ther (Heidelb). 2021 Jun;11(3):681-694. doi: 10.1007/s13555-021-00510-2. Epub 2021 Mar 18.
Narrow-band ultraviolet B (NB-UVB) phototherapy has been used for the treatment of chronic urticaria (CU), but the clinical efficacy of this treatment modality requires further evidence. A systematic review and meta-analysis of randomized clinical trials were conducted to evaluate the efficacy and safety of NB-UVB as add-on therapy in the treatment of CU.
A literature search was conducted in the Cochrane, Embase, PubMed, Web of Science, CNKI, CBM, VIP and WanFang databases up to October 2020. A total of nine studies involving 713 participants met the inclusion criteria.
Two trials showed a significant difference in the Urticaria Activity Score between therapy with NB-UVB + antihistamines and that with antihistamines alone (mean difference 8.23, 95% confidence interval [CI] 5.78-10.68, p < 0.00001). Six trials (563 participants) showed a significant benefit of NB-UVB as add-on therapy to antihistamines in the total effective rate (risk ratio [RR] 1.56, 95% CI 1.39-1.75, p < 0.00001). In terms of adverse events, no statistically significant differences were found for NB-UVB + antihistamines versus antihistamines alone (RR 1.10, 95% CI 0.67-1.79, p = 0.71). Combination therapy of NB-UVB + antihistamines yielded a significantly lower risk of recurrence (RR 0.25, 95% CI 0.14-0.44, p < 0.00001).
Our meta-analysis suggests that combination therapy of NB-UVB + antihistamines is significantly more effective in treating CU than antihistamines alone.
窄谱中波紫外线(NB-UVB)光疗已用于治疗慢性荨麻疹(CU),但这种治疗方式的临床疗效需要更多证据。我们进行了一项随机临床试验的系统评价和荟萃分析,以评估NB-UVB作为附加疗法治疗CU的疗效和安全性。
截至2020年10月,在Cochrane、Embase、PubMed、Web of Science、中国知网(CNKI)、中国生物医学文献数据库(CBM)、维普资讯(VIP)和万方数据库中进行了文献检索。共有9项涉及713名参与者的研究符合纳入标准。
两项试验显示,NB-UVB联合抗组胺药治疗与单纯抗组胺药治疗相比,荨麻疹活动评分有显著差异(平均差值8.23,95%置信区间[CI]5.78 - 10.68,p < 0.00001)。六项试验(563名参与者)显示,NB-UVB作为抗组胺药的附加疗法在总有效率方面有显著益处(风险比[RR]1.56,95%CI 1.39 - 1.75,p < 0.00001)。在不良事件方面,NB-UVB联合抗组胺药与单纯抗组胺药相比未发现统计学显著差异(RR 1.10,95%CI 0.67 - 1.79,p = 0.71)。NB-UVB联合抗组胺药治疗的复发风险显著更低(RR 0.25,95%CI 0.14 - 0.44,p < 0.00001)。
我们的荟萃分析表明,NB-UVB联合抗组胺药治疗CU比单纯抗组胺药显著更有效。